Every lot published · search any lot number before you order

TRIUMPH-1 Retatrutide Phase 3 Weight-Loss Results

TRIUMPH-1 compared retatrutide with placebo over 80 weeks. In the sponsor’s efficacy analysis, the 12 mg arm showed a 28.3% average reduction in body weight, compared with 2.2% with placebo.

TRIUMPH-1 Retatrutide Phase 3 Weight-Loss Results. 80-week placebo-controlled evidence. 12 mg arm, 80 weeks, 28.3% efficacy estimate. GLP LIFE SCIENCES · RESEARCH BRIEF 13 80-week placebo-controlled evidence Weight loss studies 12 mg arm80 weeks28.3% efficacy estimate
80-week placebo-controlled evidence. Illustration for this research brief.

80-week placebo-controlled evidence

The trial publication reports outcomes under prespecified analytical approaches. The sponsor’s headline number belongs to its stated efficacy analysis, and a reader should check the paper for how other analyses handle treatment changes or discontinuation.

How to interpret the evidence

Use the Phase 3 paper to verify the protocol and the sponsor release to trace the headline percentage to its specific table.

When comparing results, record the primary outcome, the measurement week, and whether the analysis included outcomes after treatment stopped.

Sources